JU Logo Entwürfe v2 07-15

 

Aminoglycoside antibiotics are among the most potent antibacterials, offering a number of features which make them attractive drug candidates: high efficacy, bactericidal activity of unmatched potency, lack of drug-related allergy, little effect on the host’s microbiome, and minimal interference with other medications.

The Swiss start-up company Juvabis designs next-generation aminoglycoside antibiotics that withstand mechanisms of bacterial drug-resistance and at the same time display superior tolerability due to increased target selectivity by rational design. Juvabis has been founded around a proprietary technology developed by researchers at the University of Zurich, and a pipeline of early drug candidates discovered in collaboration with researchers at the ETH Zurich and Wayne State University in Detroit.

 

Disclaimer     Terms of Use     Privacy Policy                                                                                                             Site Map          Imprint